Skip to main content
KALA logo

KALA · KALA BIO, Inc. · Metrics

Track KALA — free
$2.71 -0.31 (-10.28%) At close · Nov 20 Q2 2022 earnings call transcript
Market Cap
$1.74M
Shares
644,660
Volume · Nov 20 19.23K Avg daily vol (5 sessions) 17.3K

KALA metrics

38 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.71
Market cap
$1.74M

Price action

23 metrics
Price change (1W)
—
Price change (30D)
-29.4%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
—
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
644,660

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.2
reciprocal yield 518.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-578.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-08-08

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$20.99M
Net income (TTM)
−$10.08M
Trailing 12 months
Diluted EPS (TTM)
$-924.90
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
$-9,545.31
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$14.03

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-43.1%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-111.5%
Return on assets
-95.3%
Debt / equity
0.0
Current ratio
6.9
EBITDA (TTM)
−$38.84M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$7.23M
Latest balance sheet
Cash & equivalents
$229,000
Total assets
$10.58M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$11.04M
Capital expenditures (TTM)
—
R&D (TTM)
$6.61M
SG&A (TTM)
—
Stock compensation (TTM)
$1.84M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
16
13F filer change QoQ
+1
Institutional ownership
4.4%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
0.4%
Private-fund adviser ownership
0.4%
Active holders' share change QoQ
+659.7%
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
1.2%

Short interest

3 metrics
Short interest
2.0%
Latest settlement · 1.8 days to cover
Days to cover
1.8d
Short-squeeze score
41 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1479419 CUSIP 483119301 13F (30d) 23 filings 19 filers Visit website Investor relations